Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masatoshi Abe

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.
Dermatology and Therapy|June 19, 2024
Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled StudyYukari Okubo, Tadashi Terui, Satomi Kobayashi, et al.
American Journal of Clinical Dermatology|May 26, 2023
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled StudyTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
The Journal of Dermatology|January 10, 2020
Japanese guidance for use of biologics for psoriasis (the 2019 version)Hidehisa Saeki, Tadashi Terui, Akimichi Morita, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2025
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
Dermatology and Therapy|December 12, 2025
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 TrialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
The Journal of Investigative Dermatology|June 16, 2005
Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularisNoriyuki Suzuki, Tamio Suzuki, Katsuhiko Inagaki, et al.
Thoracic Cancer|March 2, 2026
Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma CellsYoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, et al.
The Journal of Dermatology|February 28, 2015
Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patientsHidehisa Saeki, Shinichi Imafuku, Masatoshi Abe, et al.
European Journal of Dermatology : EJD|November 18, 2015
Adherence to oral and topical medication in 445 patients with tinea pedis as assessed by the Morisky Medication Adherence Scale-8Yuichiro Tsunemi, Shinya Abe, Miwa Kobayashi, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.
Dermatology and Therapy|June 19, 2024
Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled StudyYukari Okubo, Tadashi Terui, Satomi Kobayashi, et al.
American Journal of Clinical Dermatology|May 26, 2023
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled StudyTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
The Journal of Dermatology|January 10, 2020
Japanese guidance for use of biologics for psoriasis (the 2019 version)Hidehisa Saeki, Tadashi Terui, Akimichi Morita, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2025
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
Dermatology and Therapy|December 12, 2025
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 TrialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
The Journal of Investigative Dermatology|June 16, 2005
Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularisNoriyuki Suzuki, Tamio Suzuki, Katsuhiko Inagaki, et al.
Thoracic Cancer|March 2, 2026
Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma CellsYoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, et al.
The Journal of Dermatology|February 28, 2015
Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patientsHidehisa Saeki, Shinichi Imafuku, Masatoshi Abe, et al.
European Journal of Dermatology : EJD|November 18, 2015
Adherence to oral and topical medication in 445 patients with tinea pedis as assessed by the Morisky Medication Adherence Scale-8Yuichiro Tsunemi, Shinya Abe, Miwa Kobayashi, et al.
Pageof 10